Bendamustine and Rituximab in Combination With Copanlisib for the Treatment of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Conditions:   Lymphoid Leukemia;   Non-Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma Interventions:   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Biological: Rituximab;   Drug: Bendamustine;   Drug: Bendamustine Hydrochloride Sponsors:   University of Washington;   National Cancer Institute (NCI);   Bayer Not yet recruiting
Source: - Category: Research Source Type: clinical trials

Related Links:

CONCLUSIONS: Our results using AQX-435 demonstrate that SHIP1 activation may be an effective novel therapeutic strategy for treatment of B-cell neoplasms, alone or in combination with ibrutinib. PMID: 31831562 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Publication date: Available online 7 December 2019Source: Urology Case ReportsAuthor(s): Margaret M. Mansbridge, Jonathon R. Parker, Sewwandi Francisco, Scott T. McClintockAbstractIncidental diagnosis of haematolymphoid disorders in prostate tissue is rare, with the largest study in the literature reporting a 0.37% incidental lymphoma diagnosis in prostate and associated lymph node tissue. B cell lymphocytosis (MBL) is a relatively recently defined disease entity. The authors present the diagnosis and management of a patient diagnosed with incidental MBL on transurethral resection of prostate (TURP), performed for symptoma...
Source: Urology Case Reports - Category: Urology & Nephrology Source Type: research
Authors: Woyach JA Abstract The management of chronic lymphocytic leukemia (CLL) has undergone dramatic changes over the previous 2 decades with the introduction of multiple new therapies and new combinations. Management of the newly diagnosed asymptomatic patient has not significantly changed outside of the development of a number of prognostic factors and the CLL International Prognostic Index, which is helpful in discussions regarding prognosis and likelihood of requiring treatment. When therapy is required, initial treatment of most patients now includes either the Bruton tyrosine kinase inhibitor ibrutinib or ...
Source: Hematology ASH Education Program - Category: Hematology Tags: Hematology Am Soc Hematol Educ Program Source Type: research
Abstract An 11-year-old neutered male miniature American Eskimo dog was presented for routine dental cleaning with moderately enlarged submandibular, prescapular, and popliteal lymph nodes. On pre-anesthetic blood analysis a moderate, poorly regenerative anemia and marked lymphocytosis were observed. Although cytologic evaluation of a lymph node aspirate was interpreted as lymphoma, a complete blood cell count, flow cytometric immunotyping of blood leukocytes, and serum electrophoresis identified B-cell chronic lymphocytic leukemia. Chemotherapy with chlorambucil was recommended. PMID: 31814644 [PubMed - in process]
Source: The Canadian Veterinary Journal - Category: Veterinary Research Authors: Tags: Can Vet J Source Type: research
ConclusionVenetoclax therapy in a real-world cohort offered modest benefits in heavily pretreated patients. Adverse events were observed at a greater incidence than in the clinical trials. A wide heterogeneity of venetoclax dose escalation, multiagent combinations, and timing of initiation were identified and require investigation in subsequent clinical trials.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
This study compared time to next treatment (TTNT), health care resource utilization (HRU), and total direct costs among patients with chronic lymphocytic leukemia (CLL) initiating front-line ibrutinib single agent (Ibr) or CIT.Materials and MethodsOptum Clinformatics Extended DataMart De-Identified Databases were used to identify adults with ≥ 2 claims with a CLL diagnosis initiating front-line Ibr or CIT from February 12, 2014 to June 30, 2017. Inverse probability of treatment weighting was used to control for potential differences in baseline characteristics between the Ibr and CIT cohorts. Two periods were consi...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Chimeric antigen receptor (CAR)-T cell therapy is a new and powerful class of cancer immunotherapy [1,2]. Clinical trials of CAR-T cell therapy targeting the B-cell marker CD19 have shown promising results for the treatment of hematologic malignancies, including acute lymphoblastic leukemia (ALL) [3 –7], chronic lymphocytic leukemia (CLL) [8,9], and non-Hodgkin lymphoma (NHL) [10,11]. CAR-T cell therapy targeting B-cell maturation antigen (BCMA) has also been demonstrated to be effective for treating multiple myeloma (MM) [12–15].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Authors: Iskierka-Jażdżewska E, Robak T Abstract Introduction: During recent years, therapy in chronic lymphocytic leukaemia (CLL) has changed dramatically. The introduction of small molecule inhibitors has shown remarkable clinical efficacy in both previously untreated and relapsed CLL patients. However, these therapies are associated with an increased risk of specific adverse events. Selection of the best therapeutic approach for patients with CLL should be based on an assessment of general condition, comorbidities, and most importantly, the individual risk of serious side effects.Areas covered: The review pres...
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research
FRIDAY, Nov. 22, 2019 -- The U.S. Food and Drug Administration has granted supplemental approval to Calquence (acalabrutinib) for treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), the agency announced...
Source: - Daily MedNews - Category: General Medicine Source Type: news
(Ohio State University Wexner Medical Center) On Nov. 21, 2019, the US Food and Drug Administration (FDA) approved the use of the drug acalabrutinib for first-line therapy in chronic lymphocytic leukemia and small cell lymphoma. This is the first full approval of the targeted drug therapy, which was developed and tested at The Ohio State University Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, in collaboration with the pharmaceutical partner, Acerta Pharma.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Leukemia | Lymphoma | Research | Rituxan | Treanda